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After heptavalent pneumococcal conjugate vaccine 
(PCV7) was marketed in France, Spain, Belgium, and 
England and Wales (United Kingdom), invasive disease 
from non-PCV7 serotypes (NVT) increased. Adjusted se-
rotype-speciﬁ   c incidences among children <15 years of 
age were compared between 1999–2002 (prevaccine) and 
2005–2006 (postmarketing). Vaccine coverage increased 
to ≈32%–48% in France, Spain, and Belgium but remained 
<1% in England and Wales. Serotype 1 incidence rose in all 
age groups and countries (incidence rate ratio [IRR] 1.3–
4.2; p<0.004), independently of PCV7 use, but incidence 
of serotypes 7F and 19A increased most in France, Spain, 
and Belgium (IRR 1.9–16.9 in children <5 years; p<0.001), 
where PCV7 coverage was greater. Vaccine-induced re-
placement of PCV7 serotypes possibly contributed to NVT 
increases, as did secular trends. New vaccines target-
ing these serotypes are available, but serotype dynamics 
needs further exploration that accounts for underreporting 
and prevaccine trends.
S
treptococcus pneumoniae is a leading cause of menin-
gitis and septicemia worldwide. More than 90 serotypes 
have been identiﬁ  ed for S. pneumoniae, but serotype dis-
tribution differs by area and changes over time (1–3). The 
heptavalent pneumococcal conjugate vaccine (PCV7) tar-
gets the 7 serotypes—4, 6B, 9V, 14, 18C, 19F, and 23F—
that most commonly caused pediatric invasive pneumococ-
cal disease (IPD) in the United States. Widespread PCV7 
use in the United States since 2000 led to rapid and dramat-
ic decreases in vaccine serotypes and an overall decrease of 
IPD incidence (4). 
In Europe, PCV7 was licensed for pediatric use in 
2001 and marketed in Spain and France in 2001, England 
and Wales in 2002, and Belgium in 2004; the 7 serotypes 
accounted for 68%–77% of IPD cases in children <2 or 
<5 years of age (5–8). Vaccination policies from market-
ing to introduction of PCV7 into the universal vaccination 
schedule differed among countries. In Spain, Belgium, and 
France, vaccination aimed to reach a progressively increas-
ing proportion of children <2 years of age, resulting in low 
but increasing vaccine coverage (36%–50% of young chil-
dren in 2005–2006) because PCV7 was not free for all of 
them (6,7). In England and Wales, until late 2006 PCV7 
was recommended only for medical risk groups, and pop-
ulation-level vaccine coverage was negligible. PCV7 was 
introduced in the national universal program and delivered 
free in France and England and Wales in 2006 and Belgium 
in 2007. In Spain, free universal vaccination was limited to 
the Madrid region beginning in 2006.
Several PCV7 postlicensure studies in the United 
States and European countries have described substantial 
increases in non-PCV7 vaccine serotypes (NVTs) (6,7,10–
13). These ﬁ  ndings raised concern that vaccine use could 
lead to replacement of PCV7 serotypes by NVTs, as oc-
curred with pneumococcal carriage (14). 
In Spain, Belgium, France, and England and Wales, 
NVT disease increased substantially between marketing 
and introduction of PCV7 into the universal schedule, when 
vaccine use was moderate in Spain, Belgium, and France 
and negligible in England and Wales. Considering that a 
10-valent vaccine and a 13-valent conjugate vaccine are 
licensed in the European Union (EU), a better understand-
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ing of the dynamics of the additional serotypes is needed 
to help decision making on future vaccine strategies. This 
study describes and compares temporal trends of PCV7 se-
rotypes and NVTs among children in 4 European countries, 
taking into account the levels of PCV7 use. We focused on 
the emergence of serotypes 1, 7F, and 19A because they 
were responsible for most of the NVT increase.
Methods
This population-based study is based on surveillance 
data collected prospectively by the national reference labo-
ratories (NRLs) of Spain, Belgium, France, and England 
and Wales during July 1996–June 2006. (In the United 
Kingdom, Scotland and Northern Ireland were not included 
in this study because they use separate surveillance sys-
tems.) IPD isolates were referred by laboratories through-
out each country to the NRL. IPD surveillance among 
children was enhanced in England and Wales, France, and 
Belgium starting in 1996, 2002, and 2005, respectively, by 
encouraging microbiologists to systematically refer pneu-
mococcal isolates to the NRL for typing.
Deﬁ  nitions and Inclusion Criteria
We included all IPD cases, deﬁ  ned by isolation of S. 
pneumoniae from a normally sterile ﬂ  uid in children <15 
years of age and referred to the NRL of their country. One 
isolate per disease episode was used in the analysis. Se-
rotypes targeted by PCV7 were grouped as vaccine types 
(PCV7 types). All other serotypes were considered NVTs. 
Meningitis was deﬁ  ned as isolation of S. pneumoniae in 
cerebrospinal ﬂ  uid (CSF).
An epidemiologic year was July through June. A pre-
vaccine period was deﬁ  ned as the 3 epidemiologic years 
during July 1999–June 2002. The postmarketing period 
was 2005–2006.
Microbiologic Testing
Serotype and antimicrobial susceptibility were deter-
mined by each NRL as described (9,15–17). In Spain, all 
strains of serogroups 6 and 19 were subjected to PCR sero-
type identiﬁ  cation (18). In Belgium during 1996–2004 (be-
fore PCV7 marketing), 36% of isolates had the serogroup 
but not the serotype determined (17% for serogroup 19). 
However, all serogroup 19 isolates from children <2 years 
of age were typed, and during the postmarketing period, the 
serotype was determined for all isolates received. Isolates 
with missing serotype were assumed to follow the same 
serotype distribution as isolates from the same serogroup, 
by year and patient age group.
Isolates were considered susceptible, intermediate, or 
resistant to antimicrobial drugs according to Clinical and 
Laboratory Standards Institute criteria (penicillin interme-
diate and resistant, MIC 0.12–1.0 mg/L and MIC >1 mg/L, 
respectively; erythromycin resistant, MIC >0.5 mg/L) (19). 
England and Wales data on antimicrobial drug resistance 
were not available for this study.
Vaccine Coverage and Macrolide Use
Because studies estimating vaccine coverage used dif-
ferent methods among countries, we used vaccine doses to 
estimate a proxy of vaccine coverage. Data on monthly vac-
cine doses sold or distributed were provided by the PCV7 
manufacturer (Wyeth, Brussels, Belgium; Madrid, Spain; 
Maidenhead, UK; and Paris, France) and by the Health 
Protection Agency for doses distributed by the UK Depart-
ment of Health. Assuming that all doses were administered 
to children <2 years of age at an average of 3 doses per 
child (allowing for missed doses and catch-up schedules), 
we calculated the proportion of children <2 years of age 
who should have received an average of 3 PCV7 doses. We 
also calculated the number of vaccine doses distributed per 
1,000 children <5 years of age for comparison with sero-
type-speciﬁ  c incidences in children <5 years of age.
We collected data on use of antimicrobial drugs from 
the European Surveillance of Antimicrobial Consumption 
(20). We compared these data with the serotype-speciﬁ  c 
incidence of antimicrobial drug–resistant isolates.
Data Analysis
For all incidence calculations, we adjusted numbers of 
cases to the rate of underreporting to the NRL to estimate 
total numbers of cases and control for surveillance en-
hancement over time. Underreporting rates were calculated 
by country, year, and age group by dividing the respective 
number of cases with an isolate typed at the NRL by the 
total number of laboratory-conﬁ  rmed IPD cases estimated 
in the country. Total numbers of IPD cases were estimated 
by different methods: in Belgium and France, through pe-
riodic capture–recapture studies and correction for labora-
tory coverage (7,21); in England and Wales, by reconcili-
ation of 2 large datasets (22); in Spain, by calculation of 
hospital underreporting rates as a proxy (23). Age-speciﬁ  c 
incidence rates were computed by dividing adjusted num-
bers of cases by the respective midperiod population of 
each country and age group, by using population ﬁ  gures 
from Eurostat for Spain and from the national institutes for 
statistics of Belgium, France, and England and Wales. For 
serotype-speciﬁ  c incidence calculations, cases with miss-
ing serotype data were accounted for by multiplying the 
overall incidence by the yearly proportions of serotype-
speciﬁ  c disease in each age group (12).
Trends in incidence over time were tested for linear 
model by the t test, except for France because of missing 
data points; this model showed an overall better ﬁ  t for the 
3 studied serotypes. Correlation between vaccine doses 
per 1,000 children <5 years of age and serotype-speciﬁ  c 
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incidence over years was tested by the Pearson correlation 
test, allowing for a 6-month lag between vaccine use and 
incidence. We also compared the annual average of sero-
type-speciﬁ  c incidence of the prevaccine period with the 
postmarketing period and computed incidence rate ratios 
(IRRs) and their exact 95% conﬁ  dence intervals; p values 
were calculated by the Fisher exact test. We considered p 
values <0.05 signiﬁ  cant. All statistical analyses were cal-
culated by using STATA version 10.1 (StataCorp, College 
Station, TX, USA).
Results
PCV7 Coverage
PCV7 use began in Spain in 2000–2001, France in 
2001–2002, Belgium in 2004–2005, and England and 
Wales in 2005–2006 and increased gradually in the ﬁ  rst 
3 countries (Figure 1). In 2005–2006, the proportion of 
children <2 years of age who had received an average of 3 
PCV7 doses was ≈33% in Spain, ≈48% in France, ≈42% in 
Belgium, and <1% in England and Wales.
Overall Incidence
During July 1996–June 2006, the NRLs of the 4 coun-
tries reported 13,584 IPD cases among children <15 years 
of age: 3,170 cases in Spain, 2,862 in Belgium, 2,188 in 
France, and 5,364 in England and Wales. Data were not 
available from France from 1997–98 through 2000–2001 
because NRL activities stopped in 1997 and began again 
in 2001. The proportion of conﬁ  rmed IPD cases typed at 
the NRLs increased during the study period because of im-
proving reporting of each NRL (Table 1). IPD incidence 
per 100,000 children <15 years of age increased during the 
10-year period in Spain, Belgium, and England and Wales 
from 14.0 to 18.5, 20.1 to 28.2, and 6.1 to 10.6, respec-
tively, but remained fairly stable in France, ≈7.0.
Isolates from CSF represented 15% of invasive iso-
lates in patients <15 years in Spain, 11% in Belgium, 16% 
in England and Wales, and 32% in France. Because blood 
isolates were underrepresented in France, NRL data were 
adjusted to the CSF/blood distribution reported by nation-
al epidemiologic surveillance, by year and age group (7). 
Only adjusted data are presented here.
PCV7-Type and NVT IPD Cases
In children <5 years of age, incidence of PCV7-type 
disease started to decrease shortly after PCV7 introduction 
in Spain, Belgium, and France; the decrease was inversely 
related to increasing vaccine sales (Figure 1). Between the 
prevaccine period and the last study year (2005–2006), 
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Figure 1. Incidence of pediatric invasive pneumococcal disease among children <5 years of age, by heptavalent pneumococcal conjugate 
vaccine (PCV7) (black lines) and non-PCV7 (red lines) serotypes, for A) Spain, B) Belgium, C) England and Wales, and D) France, 1996–
2006. Estimated vaccine coverage is the annual number of PCV7 schedules per 100 children <2 years of age, assuming an average of 3 
doses administered to each child. Vaccine coverage is not visible for England and Wales because it remains <1%.Pneumococcal Serotypes in 4 European Countries
PCV7-type IPD signiﬁ   cantly declined by 58%, 22%, 
and 52%, respectively, in these 3 countries (Table 2). In 
England and Wales, where vaccine sales were negligible, 
PCV7-type IPD increased by 25%, but the proportion of 
IPD caused by PCV7-type decreased slightly, from 75% to 
70% (p = 0.004). In older children, PCV7-type IPD showed 
no clear trend, except in Belgium, where it signiﬁ  cantly de-
creased (Figure 2; Table 3).
In contrast, incidences of NVT signiﬁ  cantly increased 
in all 4 countries during the 10-year period (p<0.001), 
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Table 1. Cases of invasive pneumococcal disease, underreporting rates, and numbers adjusted for underreporting among children  
<15 years of age, 4 European countries, 1996–2006* 
Country/epidemiologic year  Total typed 
Underreporting, 
%† 
Total 
adjusted‡
Serotype 
PCV7 types  NVT  1 7F  19A
Spain
 1996–97  155 18 869 544 325 62 0 28
 1997–98  179 19 919 590 329 41 15 5
 1998–99  191 26 740 415 326 81 16 31
 1999–00  211 30 713 463 250 88 7 20
 2000–01  252 28 901 580 322 107 11 54
 2001–02  301 30 1,014  613 401 91 3 44
 2002–03  426 39 1,092  528 564 131 31 97
 2003–04  434 45 959 433 526 106 22 128
 2004–05  528 43 1,228  367 860 207 70 198
 2005–06  493 42 1,185  288 896 312 74 168
Belgium
 1996–97  160 44 363 225 138 34 7 11
 1997–98  202 46 436 272 165 32 9 32
 1998–99  185 55 339 179 159 31 7 29
 1999–00  197 55 356 218 138 40 5 23
 2000–01  256 56 455 293 162 52 11 32
 2001–02  295 65 454 268 186 48 11 32
 2002–03  370 75 497 283 214 66 15 42
 2003–04  382 73 521 270 251 91 20 42
 2004–05  437 76 578 315 263 103 22 45
 2005–06  378 75 506 190 316 102 37 58
France§ 
 1996–97  258 33 773 547 226 52 0 40
 1997–98  NA NA NA NA NA NA NA NA
 1998–99  NA NA NA NA NA NA NA NA
 1999–00  NA NA NA NA NA NA NA NA
 2000–01  NA NA NA NA NA NA NA NA
 2001–02  320 41 775 497 278 64 15 53
 2002–03  399 46 864 531 333 92 32 87
 2003–04  384 47 811 424 387 119 23 90
 2004–05  438 54 806 359 447 159 41 71
 2005–06  389 50 774 277 497 157 62 93
England and Wales 
 1996–97  378 60 630 315 315 45 13 13
 1997–98  429 62 689 462 226 43 14 26
 1998–99  438 67 654 473 181 24 10 16
 1999–00  429 64 666 453 213 36 8 37
 2000–01  518 71 735 562 173 37 23 21
 2001–02  557 72 770 549 221 37 14 28
 2002–03  541 67 804 579 224 37 24 30
 2003–04  627 71 889 628 261 67 16 37
 2004–05  672 74 914 590 324 114 20 39
 2005–06  775 76 1,014  640 374 139 38 38
*PCV7, heptavalent pneumococcal conjugate vaccine; PCV7 types, serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F; NVT, non-PCV7 vaccine serotypes, i.e., 
serotypes not included in the PCV7 vaccine; NA, not available. 
†Underreporting rate = number of cases for which an isolate was typed at the national reference laboratory on the total number of laboratory-confirmed 
invasive pneumococcal cases estimated in the country (by capture–recapture or other methods) in children <15 years of age. 
‡The sum of PCV7 types and NVT cases may slightly differ from the total adjusted because of rounding. 
§Data have been adjusted for ascertainment and for the distribution of blood/cerebrospinal fluid isolates. RESEARCH
mainly from 2000–2002 onward (Figures 1, 2). From the 
prevaccine period to 2005–2006, NVT IPD increased sig-
niﬁ  cantly in both the <5-year and the 5–14-year age groups 
in all countries (Tables 2, 3). In each country, NVT IPD in 
the <5-year age group began to increase before PCV7 was 
introduced and gradually increased from year to year dur-
ing 2002–2006. In children 5–14 years of age, NVT IPD 
ﬂ  uctuated during the study period but mostly increased 
during 2002–2006. Serotypes 1, 7F, and 19A contributed 
most to this increase, representing 61% (range 57%–63%) 
of NVT IPD in children <15 years of age in 2005–2006. 
The dynamics of these 3 serotypes differed in terms of time 
trends and age groups affected.
Serotype 1
Serotype 1 disease increased signiﬁ   cantly in each 
country during the 10-year period in both age groups 
(Figure 3). In children <5 years of age, the increase in se-
rotype 1 began before PCV7 sales began. However, the 
largest increases occurred from 1999–2002 to 2005–2006, 
when incidence increased by 2–4-fold in both age groups 
in all countries (Tables 2, 3). Increases in the incidence of 
serotype 1 did not correlate signiﬁ  cantly with PCV7 sales, 
except in France (Pearson r = 0.903, p = 0.036). In the 5–14-
year age group, incidences were lower, but in 2005–2006, 
serotype 1 constituted in average 50% of IPD in that age 
group compared with 13% in children <5 years of age. All 
serotype 1 isolates were susceptible to penicillin. Incidence 
and proportion of erythromycin-resistant serotype 1 was 
low but increased in Belgium in 2004–2006.
Serotype 7F
Most (74%) serotype 7F cases occurred among chil-
dren <5 years of age. In this group, IPD increased sub-
stantially in each country, mostly during 2004–2006, and 
correlated signiﬁ  cantly with PCV7 sales, except in France 
(Pearson r = 0.901, p = 0.037 in Spain; r = 0.988, p = 0.002 
in Belgium; r = 0.965, p = 0.008 in England and Wales; and 
r = 0.746, p = 0.148 in France) (Figure 4). From the pre-
vaccine period to 2005–2006, incidence increased most in 
Spain and least in England and Wales (Table 2). In children 
5–14 years of age, incidence rates also increased (Table 3), 
but numbers of cases were small. All serotype 7F isolates 
were susceptible to penicillin, and only 6/315 isolates in 
children <5 years of age were erythromycin resistant.
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Table 2. Serotype-specific adjusted incidence rates of invasive pneumococcal disease in children <5 years of age before and after
marketing of PCV7, Spain, Belgium, France, and England and Wales* 
Country/serotypes 
Incidence rate†  Incidence rate ratio 
(95% CI)  p value  Prevaccine (1999–2002)  Postmarketing (2005–2006) 
Spain
  PCV7 types  26.8 11.3 0.4 (0.4–0.5)  <0.001 
  Non-PCV7 types  12.5 31.1 2.5 (2.2–2.8)  <0.001 
  1  2.7 8.1 3.0  (2.4–  3.7)  <0.001 
  7F  0.2 3.0 16.9  (8.6–37.7)  <0.001 
  19A  1.9 7.2 3.7  (2.9–4.8)  <0.001 
Belgium
  PCV7 types  38.7 30.0 0.8 (0.7–0.9)  0.002 
  Non-PCV7 types  19.7 41.3 2.1 (1.8–2.5)  <0.001 
  1  3.4 9.5 2.8  (1.9–  4.1)  <0.001 
  7F  1.1 5.9 5.3  (2.9–9.8)  <0.001 
  19A  4.4 9.7 2.2  (1.5–3.1)  <0.001 
France 
  PCV7 types  11.9 5.7 0.5 (0.4–0.6)  <0.001 
  Non-PCV7 types  4.9 9.0 1.9 (1.5–2.2)  <0.001 
  1  0.6 1.5 2.7  (1.6–4.7)  <0.001 
  7F  0.3 1.3 4.2  (2.2–8.6)  <0.001 
  19A  1.3 2.4 1.9  (1.3–2.7)  <0.001 
England and Wales 
  PCV7 types  14.6 18.2 1.3 (1.1–1.4)  <0.001 
  Non-PCV7 types  4.7 7.8 1.6 (1.4–1.9)  <0.001 
  1  0.5 1.9 3.8  (2.6–5.8)  <0.001 
  7F  0.4 0.9 2.2  (1.3–3.7)  0.002 
  19A  0.8 1.0 1.3  (0.8–2.0)  0.271 
*PCV7, heptavalent pneumococcal conjugate vaccine; CI, confidence interval. Marketing indicates that the vaccine was marketed and available for use in 
the country but not introduced in the vaccine schedule free of charge. Vaccine coverage differed by country during this period, ranging from 33% to 48% 
in Spain, Belgium, and France but <1% in England and Wales. PCV7 types include serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. 
†Cases per 100,000 children <5 years of age. Data for 1999–2002 are annual averages. Prevaccine period is 2001–2002 for France (data not available 
for previous years). Pneumococcal Serotypes in 4 European Countries
Serotype 19A
Serotype 19A disease affected predominantly children 
<5 years of age (94% of cases), for whom incidence rates 
more than doubled (IRR range 2.4–6.8) over the period 
(Figure 5). Incidence had already increased before PCV7 
sales started in Belgium, Spain, and England and Wales, 
but the trend was signiﬁ  cant only in Belgium (during 1996–
2004). After PCV7 marketing, increases correlated signiﬁ  -
cantly with vaccine sales in Spain and Belgium (Pearson 
r = 0.929 and 0.884, p = 0.022 and 0.047, respectively). 
From the prevaccine period to 2005–2006, 19A incidence 
signiﬁ  cantly increased in Spain, France, and Belgium (Ta-
ble 2); in England and Wales, the 27% increase was not 
signiﬁ  cant. In children 5–14 years of age, numbers of cases 
were too small to identify any signiﬁ  cant change.
Serotype 19A isolates showed high and increasing lev-
els of antimicrobial drug resistance in Belgium, Spain, and 
particularly in France (data unavailable from England and 
Wales). In the <5-year age group, the prevalence of non-
susceptible strains ranged 0%–50% in 1996–1997 and in-
creased in 2005–2006 to 21%, 48%, and 86% for penicillin 
and 67%, 61%, and 77% for macrolides in Belgium, Spain, 
and France, respectively. Full penicillin resistance was rare 
(0%–6% of isolates). Spain and Belgium shared similar 
patterns: incidence of penicillin-susceptible 19A increased 
more than resistant strains; incidence of erythromycin-re-
sistant strains increased more than erythromycin-suscepti-
ble strains (Figure 6); in 1998–2006, the use of penicillin 
in ambulatory setting, calculated in deﬁ  ned daily doses per 
1,000 inhabitants per day, increased slightly, and macrolide 
use declined by 31%–38%. In France, where nonsuscepti-
ble isolates predominated, use of penicillin and macrolides 
initially was much higher than that in the other countries 
but declined (–17% and –37%, respectively) until 2006. In 
England and Wales where use of antimicrobial drugs was 
initially lower, macrolide use became similar to Belgium 
and Spain from 2004 onward, but data on resistance were 
not available.
Evolution of Meningitis
Numbers of meningitis cases caused by individual se-
rotypes were small, especially for serotype 1. In children 
<5 years of age, the incidence of meningitis from serotypes 
19A and 7F combined also increased signiﬁ  cantly in Spain, 
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Figure 2. Incidence of pediatric invasive pneumococcal disease among children 5–14 years of age, by heptavalent pneumococcal 
conjugate vaccine (PCV7) (black lines) and non-PCV7 (red lines) serotypes, A) Spain, B) Belgium, C) England and Wales, and D) France, 
1996–2006.RESEARCH
Belgium, and France from the prevaccine period to 2005–
06 (IRR 3.8, 4.9 and 2.3, respectively, p<0.001); in Eng-
land and Wales, it did not increase signiﬁ  cantly (IRR 1.3, 
p = 0.283).
Discussion
This study compared the dynamics of NVT disease in 
4 countries before universal PCV7 vaccination. In Spain, 
Belgium and France, serotype 1, 7F and 19A incidence in-
creased considerably under rising (though moderate) vac-
cine coverage. In England and Wales, where PCV7 use 
was negligible, serotype 1 disease increased substantially, 
7F disease rose less than in the other countries, and 19A 
disease increased nonsigniﬁ  cantly. The proportion of IPD 
caused by serotype 19A remained stable in England and 
Wales, and the incidence of meningitis caused by 19A and 
7F did not change signiﬁ  cantly, suggesting that an increase 
in case detection caused part of the changes in 19A and 7F 
incidence. Indeed, a study showed that the 21% increase 
in IPD incidence in southwest England during 1996–2005 
was no longer observed after adjustment for annual blood-
culturing rates (24).
In Spain, the marked increase in NVT occurred con-
comitantly with PCV7 use, which led several studies to 
conclude that vaccine-induced replacement of serotypes 
had largely contributed to this increase (6,11). On the basis 
of our study ﬁ  ndings, we suggest that vaccine use contrib-
uted to the increase in serotypes 7F and 19A. Both sero-
types increased markedly under increasing PCV7 coverage 
and remained stable or increased less in the countries not 
using PCV7. Increases in 19A and 7F incidences correlated 
signiﬁ  cantly with increasing vaccine sales in Spain and 
Belgium and were more pronounced in children <5 years 
of age, at whom PCV7 was aimed, than in older children. 
In Belgium and Spain, where both serotypes had already 
increased before PCV7 introduction, its slope escalated af-
ter PCV7 use. Although these data were observed under 
moderate PCV7 coverage, recent data from Belgium, Eng-
land and Wales, and France indicate additional increases 
in the adjusted incidences of serotypes 7F and 19A under 
universal vaccination (2007–08) and high vaccine cover-
age (25–27).
However, we also suggest that vaccine-induced se-
rotype replacement alone cannot explain the increase in 
NVT. First, serotype 1 rose well before PCV7 marketing 
in Belgium and Spain, affected predominantly older age 
groups, and increased in England and Wales in the absence 
of vaccine use. Second, serotype 19A increased in Belgium 
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Table 3. Serotype-specific adjusted incidence rates of invasive pneumococcal disease in children 5–14 years of age before and after
marketing of PCV7, Spain, Belgium, France, and England and Wales* 
Country/serotype 
Incidence rate†  Relative risk 
(95% CI)  p value  Prevaccine (1999–2002)  Postmarketing (2005–2006) 
Spain
  PCV7 types  1.0 0.8 0.8 (0.6–1.3)  0.387 
  Non-PCV7 types  2.1 4.6 2.2 (1.8–2.7)  <0.001 
  1  1.1 3.1 2.9  (2.3–3.7)  <0.001 
  7F  0.1 0.2 2.0  (0.7–5.6)  0.175 
  19A  0.06 0.12 2.1  (0.5–7.7)  0.226 
Belgium
  PCV7 types  3.0 1.2 0.4 (0.2–0.7)  <0.001 
  Non-PCV7 types  3.9 6.1 1.6 (1.2–2.1)  0.003 
  1  2.2 3.8 1.8  (1.2–2.6)  0.003 
  7F  0.2 0.3 1.2  (0.2–5.2)  0.728 
  19A  0.3 0.1 0.2  (0.0–1.4)  0.094 
France 
  PCV7 types  0.7 0.8 1.1 (0.7–1.6)  0.664 
  Non-PCV7 types  1.3 2.0 1.5 (1.2–2.0)  0.001 
  1  0.6 1.3 2.3  (1.6–3.4)  <0.001 
  7F  0.0 0.1 3.6  (1.0–20.2)  0.038 
  19A  0.1 0.0 0.3  (0.0–1.6)  0.116 
England and Wales 
  PCV7 types  0.7 1.0 1.4 (1.0–1.9)  0.026 
  Non-PCV7 types  0.7 2.0 2.9 (2.3–3.6)  <0.001 
  1  0.3 1.3 4.2  (3.0–5.9)  <0.001 
  7F  0.0 0.2 5.5  (1.9–18.0)  0.001 
  19A  0.05 0.1 2.1  (0.7–5.9)  0.148 
*PCV7, heptavalent pneumococcal conjugate vaccine; CI, confidence interval. Marketing indicates that the vaccine was marketed and available for use in 
the country but not introduced in the vaccine schedule free of charge. Vaccine coverage differed by country during this period, ranging from 33% to 48% 
in Spain, Belgium, and France but <1% in England and Wales. PCV7 types include serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. 
†Cases per 100,000 children 5–14 years of age. Data for 1999–2002 are annual averages. Prevaccine period is 2001–2002 for France (data not available 
for previous years). Pneumococcal Serotypes in 4 European Countries
and Spain before PCV7 use. Similarly, serotype 7F or 19A 
disease also increased in countries not using PCV7 (28–
30). Third, some EU countries with widespread PCV7 use 
did not experience similar rises (31,32).
Other factors most likely contributed to the increases. 
Cyclical trends of serotype 1 were described in Scandina-
vian countries before any PCV7 use (3,33,34). A wave of 
serotype 1 (and possibly 7F) may have occurred in these 4 
neighboring countries. Conversely, the high use of antimi-
crobial drugs, especially macrolides, allegedly favored the 
increase of nonsusceptible serotype 19A (14,35). A model-
ing study suggested that use of antimicrobial drugs played 
a larger role than did PCV7 use in the increase of resistant 
19A in the United States (36). In 3 countries in our study 
where 19A incidence (and resistant strains) increased, use 
of antimicrobial drugs was higher than in England and 
Wales where 19A stayed stable. However, incidence of 
penicillin- and erythromycin-susceptible 19A strains also 
increased in Spain and Belgium. Macrolide use decreased 
37%–41% during 1998–2006 in the 3 countries, whereas 
19A incidence increased 80%–253%. Similarly, serotype 
19A incidence increased in England and Wales after uni-
versal PCV7 vaccination despite stable macrolide use (26). 
The role of antimicrobial drugs is thus difﬁ  cult to delineate 
and suggests a synergistic effect of antimicrobial drugs 
and PCV7. Other factors for replacement have been raised 
(high prevalence of NVT carriage and low vaccine cover-
age), but they conﬂ  ict with current knowledge (37): 7F is a 
rarely carried serotype, and 19A and 7F increased further 
under higher PCV7 coverage. These conﬂ  icting views sug-
gest that factors leading to replacement disease are still not 
fully understood; its cause is probably multifactorial and 
population dependant.
Our study has several limitations. First, enhancement 
of pediatric IPD surveillance and possible changes in blood 
culture practices could not be completely controlled by our 
methods of adjusting for underreporting. This limitation 
certainly applied to England and Wales, where reconcilia-
tion of 2 datasets could not totally adjust for the increase in 
case reporting and blood culturing, which most likely con-
tributed to the increased incidence in nearly all serotypes 
studied, probably leading to overestimation of the NVT 
increase in England and Wales. Increase in blood culturing 
over time in the other countries is not suggested by the sharp 
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Figure 3. Incidence of invasive pneumococcal disease in children caused by serotype 1 for children <5 years of age (black lines) and 5–14 
years of age (red lines), in A) Spain, B) Belgium, C) England and Wales, and D) France, 1996–2006. Estimated vaccine coverage is the 
annual number of PCV7 schedules per 100 children <2 years of age, assuming an average of 3 doses administered to each child. Vaccine 
coverage is not visible for England and Wales because it remains <1%.RESEARCH
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Figure 4. Incidence of invasive pneumococcal disease in children caused by serotype 7F for children <5 years of age (black lines) and 
5–14 years of age (red lines), in A) Spain, B) Belgium, C) England and Wales, and D) France, 1996–2006. Estimated vaccine coverage 
is the annual number of PCV7 schedules per 100 children <2 years of age, assuming an average of 3 doses administered to each child. 
Vaccine coverage is not visible for England and Wales because it remains <1%.
Figure 5. Incidence of invasive pneumococcal disease in children caused by serotype 19A for children <5 years of age (black lines) and 
5–14 years of age (red lines), in A) Spain, B) Belgium, C) England and Wales, and D) France, 1996–2006. Estimated vaccine coverage 
is the annual number of PCV7 schedules per 100 children <2 years of age, assuming an average of 3 doses administered to each child. 
Vaccine coverage is not visible for England and Wales because it remains <1%.Pneumococcal Serotypes in 4 European Countries
decrease in PCV7-type IPD, the similar trends in serotype-
speciﬁ   c meningitis incidence (based on CSF isolation), 
and data on blood cultures in hospitals in Belgium (+13% 
from 1999–2002 to 2005–2006 while NVT IPD increased 
210%). Second, missing serotype data (more frequent in 
the prevaccine period) may have led to imprecision in se-
rotype distributions; however, similar age-speciﬁ  c PCV7-
type and NVT distributions and trends were observed 
in other studies in Belgium, France, Spain, and England 
(5–8,24), PCV7 serotype coverage did not vary with the 
geographic origin of pneumococcal strains in France (7), 
and the age and sample distribution of children for whom 
serotype information was available did not differ from that 
of other children in the Belgium dataset. Finally, estima-
tion of vaccine coverage assumed that all PCV7 doses were 
administered at an average schedule of 3 doses for chil-
dren <2 years of age. This method may overestimate PCV7 
coverage because a proportion of children are likely to be 
incompletely vaccinated given the high cost of PCV7 paid 
for by parents (38), but it may also underestimate coverage 
because many children received fewer doses in catch-up 
vaccination. However, coverage values were close to those 
estimated by population surveys (6,7,11,38).
Such an ecologic study cannot determine which rise in 
disease incidence is attributable to vaccine, secular trends, 
or use of antimicrobial drugs, and other possible factors 
may have contributed. However, the strength of this study 
is in the comparison of epidemiologic changes in 4 coun-
tries showing variations in serotype dynamics, vaccine use, 
and antimicrobial drug use.
The increase in incidence of serotypes 1, 7F, and 19A 
has partly countered the positive impact of PCV7 on over-
all IPD incidence in the ﬁ  rst 2–5 years of nonuniversal vac-
cine use in Belgium, France, and Spain. The new 10-valent 
(1 and 7F) or 13-valent (1, 7F, and 19A) conjugate vaccines 
include these serotypes. However, a better understanding 
of serotype dynamics and contribution of vaccine and an-
timicrobial drug use is essential to guide decisions on the 
implementation of new vaccines and to assess their impact. 
Multicountry studies are useful for comparing serotype dy-
namics among population groups that have different levels 
of vaccine and antimicrobial drug use, but analyses should 
account for underreporting and prevaccine trends.
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